Category - Markets

Rodman & Renshaw has launched coverage of Nanosphere (NASDAQ:NSPH) with a “buy” rating and price target of $2. The stock closed at 87 cents on Monday. “In our view, the company’s Verigene system and test panels are...

Rodman & Renshaw has started coverage of BioSpecifics Technologies (NASDAQ:BSTC) with a “buy” rating and 12-month price target of $60. The stock closed at $35.97 on Monday. The company’s sole product is the...

Leerink Partners has initiated coverage of Proteostasis Therapeutics (NASDAQ: PTI) with an “outperform” rating and $13 price target in 12 months. The stock closed at $5.56 on Friday. Proteostasis’ lead candidate, PTI...

H.C. Wainwright has initiated coverage of Paratek Pharmaceuticals (NASDAQ:PRTK) with a “buy” rating and $32 price target. The stock closed at $15.51 on Friday. Paratek’s lead drug, omadacycline, is a broad-spectrum...

H.C. Wainwright has launched coverage of Actinium Pharmaceuticals (NASDAQ:ATNM) with a “buy” rating and a price target of $8. The stock closed at $1.98 on Friday. “We believe that due to a long history of pivotal...

Mark Breidenback of H.C. Wainwright has assumed coverage of uniQure NV (NASDAQ:QURE) with a “buy” rating and $30 price target. The stock closed at $14.89 on Tuesday. uniQure is developing gene therapies as long-acting...

William Blair & Co. has initiated coverage of Collegium Pharmaceutical (NASDAQ:COLL) with an “outperform” rating and price target of $35. The stock closed at $19.25 on Thursday. Collegium’s lead product, Xtampza ER...

Titan Medical (OTCQX:TITXF; TSX:TMD) has closed a public offering of 11,670,818 units at a price of 90 cents each for gross proceeds of $10.5-million. Each unit consists of one common share and one warrant, with each...

Roth Capital Partners has initiated coverage of Bionomics (OTCQX:BNOEF; ASX:BNO) with a “buy” rating and AUD$1.50 price target. The stock closed at 32 cents on Tuesday.“We believe a significant disconnect exists on the...

Leerink Partners has downgraded Carbylan Therapeutics (NASDAQ:CBYL) to “market perform” from “outperform” and slashed its price target to $1.83 from $15 after the company reported a disappointing Phase 3 readout for...